Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of cases of pancreatic cancer, and prognosis for PDAC remains poor despite treatment advances. One reason is that PDAC downregulates the display of antigens on the surface of tumor cells, helping it evade the patient’s immune system and therapies involving immune checkpoint inhibitors.